Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S.C. Park, Y.A. Kang, B.H. Park, E.Y. Kim, M.S. Park, Y.S. Kim, S.K. Kim, J. Chang, J.Y. Jung (Seoul, Republic Of Korea). Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Eur Respir J 2012; 40: Suppl. 56, 4373

Member's Comments

Carrabba Maria - 05.09.2012 10:23
Dear Park, I find your poster very interisting and of value to improve the field of HCAP. Indeed, it is a controversial field and there are many things to still understand. Your analysis and the score you propose is of worth. I`m interested in the field of HCAP too and I`d like to try to apply your score on my population of HCAP Italian patients. I`m curious to see ifit works and compare my results with yours, indeed I`ve found that my HCAP population is similar to yours. I`ve recently pubblished my investigation on ERJ 2012 (it is still onlyne). Would you allow me to do it, please? Maybe, if you would like, I`ll be very glad to do it together. I`m looking forward for your answer. Many thanks for your kind attention. Best wishes Maria Carrabba (maria.carrabba@gmail.com) Internal Medicine Department - Universita` degli Studi di Milano, Italy

Related content which might interest you: Comparison of the predictive performance of severity assessment tools in community-acquired or health care-associated pneumonia Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia Year: 2013 Evaluation of nursing and health care-associated pneumonia patients with poor performance status. Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Is health care-associated pneumonia itself a predisposing factor for multi-drug resistant organisms? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Guideline-concordant therapy and outcomes in healthcare-associated pneumonia Source: Eur Respir J 2011; 38: 878-887 Year: 2011 Epidemiology, antimicrobial resistance and clinical outcomes in nursing home associated pneumonia compared to community acquired pneumonia Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis Source: Eur Respir J 2015; 45: 1353-1363 Year: 2015 The APO-audit in the primary health care of archangelsk region: the way to the effective therapy of community-acquired respiratory infections Source: Annual Congress 2009 - Diagnostic strategies in primary respiratory care Year: 2009 Late-breaking abstract: The differences in clinical presentations between severe health care-associated pneumonia and severe community-acquired pneumonia: A single center experience Source: Annual Congress 2011 - Aetiology, diagnosis and outcomes in community-acquired pneumonia Year: 2011 Improving antibiotic utilisation for nosocomial pneumonia Source: International Congress 2019 – Multidrug resistance in nosocomial pneumonia: burden, magnitude and solution Year: 2019 Predicting bacteraemia or rapid identification of the causative pathogen in community acquired pneumonia: where should the priority lie? Source: Eur Respir J 2016; 48: 619-622 Year: 2016 Verifying the antibiotic selection algorithm in the new Japanese pneumonia guidelines - Is algorithm-discordant treatment associated with increased mortality of healthcare-associated pneumonia? Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Future antibiotics and current practices for treating respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=255 Year: 2004 Improving outcomes from community-acquired pneumonia: we need to be more sophisticated about cause and effect Source: Eur Respir J 2012; 39: 7-8 Year: 2012 Improving outcomes from community-acquired pneumonia: we need to be more sophisticated about cause and effect Source: Eur Respir J 2011; 39: 7-8 Year: 2012 Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia Source: Eur Respir J 2009; 33: 394-400 Year: 2009 Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines Source: Eur Respir J 2003 Dec 01;22(6):876-882 Year: 2003 Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia Source: Guideline 2018 Year: 2019 Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia Source: ERJ Open Res, 4 (2) 00028-2018; 10.1183/23120541.00028-2018 Year: 2018 Epidemiology, treatment and outcomes of nosocomial pneumonia due to Gram-negative bacteria Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007